Search DIAN Tissue Requests
Tammie Benzinger
Quantification of Neuroinflammation in Autosomal Dominant Alzheimer's Disease Using Small-block Brain Specimen imaged by Diffusion Basis Spectrum Imaging (DBSI)
08/16/2022
withdrawn
DIAN-T2205
to assess the value of DBSI for the study of ADAD by comparing post-mortem MRI signals with histologic data
Pharma partner
Comprehensive analyses of the soluble microtubule binding region (MTBR) in Alzheimer disease progression
08/17/2022
approved
DIAN-T2206
To test the performance of a pharma partner's antibody to identify unique soluble tau MTBR epitopes
Henderson
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC modelsfor AD and PD
09/02/2022
approved
DIAN-T2207
AD/ADRD phenotypic characterization of iPSC neurons and microglia. Aim 2.1: We will differentiate and characterize cell lines into cortical neurons and microglia using established and validated protocols. Aim 2.2: We will characterize cell cultures and media supernatant for established AD biomarkers, including total tau, phosphorylated tau (Thr181), A1-40, and A1-42, neurofilament light (NfL), alpha-synuclein, cytokines and chemokines, immune profiling with CYTOF, proteomics, and comparative analyses to cerebrospinal fluid (CSF) biomarkers from the same donor.
Ralph A. Nixon
PSEN FAD mutation effects on autophagy-lysosomal pathway related gene regulation
09/12/2022
approved
DIAN-T2208
Transcriptomic analysis of PSEN1 FAD mutations
Transcriptomic analysis of PSEN2 FAD mutations
Nikolaos Robakis
Effects of PS1 FAD mutants on brain angiogenesis.
10/17/2022
not approved
DIAN-T2209
Examine whether VEGFR2 dimerization, VEGFR2/CTF1 peptide, VEGFR2 complexes, VE-cadherin angiogenic complexes and levels of VEGF ligand differ in human FAD brains compared to control brains.
Randall Bateman
DIAN-TU-001 Gantenerumab Open Label Extension Study
01/27/2023
approved
DIAN-T2301
The primary objective of the DIAN-TU-001 Gant OLE (3 years study duration) is to determine if continued treatment with Gant at a target dose of 1500 mg (subcutaneous administration, every 2 weeks) can result in continued or complete removal of brain amyloid plaque using cerebral amyloid imaging by PiB PET.
The key secondary objective of the OLE is to evaluate the efficacy of Gant in reducing disease progression and will be assessed for the following key secondary efficacy outcome measures, such as CSF and plasma biomarkers.
Cruchaga
Identification of mutation-specific networks: deep molecular profiling
02/13/2023
approved
DIAN-T2302
Identification and Characterization of Cell-Specific Transposable Elements Implicated on Alzheimer Disease and Healthy Aging
To generate neuron and microglia specific ATAC-seq, CAGE-seq, DNA methylation and long-reads RNA-seq
Eain Murphy (David Butler, Co-Invesitigator)
Alzheimer’s Disease associated pathology induced by neurotropic viral infection.
03/03/2023
approved
DIAN- T2303
Establish biomarkers and activity of SU110 and SU134 in iPSC-derived models of familial AD.
Do herpesvirus infections of neurons and glial cells produce neurodegenerative changes similar to those seen in Alzheimer’s Disease?
Assess the efficacy of anti-tau intrabodies to lower AD pathology in familial iPSC derived neurons with APP V717I iPSC mutation
Carlos Cruchaga
Functional characterization of brain circular RNAs in Alzheimer disease using induced pluripotent stem cell models
04/04/2023
approved
DIAN-T2304
To analyze the role of circHOMER1 in AD-related molecular phenotypes using cellular models
Bart De Strooper
the role of presenilin mutation in microglia cell states
04/14/2023
approved
DIAN-T2305
Profiling the gamma-secretase substrate proteome in PSEN1 H163R iPSC-derived microglia.
Characterizing the transcriptional and functional phenotype of human PSEN1 H163R microglia in a humanized chimeric AD mouse model.